placeholder.png

PARTNERSHIP AND EXHIBITION PROSPECTUS

25-28 April 2024 | SMX Manila Convention Centre, Manila
placeholder.png

PARTNERSHIP PROSPECTUS

placeholder.png

PARTNERSHIP AND EXHIBITION PROSPECTUS

25-28 April 2024 | SMX Manila Convention Centre, Manila
placeholder.png

PARTNERSHIP PROSPECTUS

Exhibition and floor plan

10 November, 2022 No Comments

APGC 2024 Manila will feature a vibrant and engaging exhibition experience, fully catered and featuring an integrated plan that facilitates e-poster display area and tours,

Read More »

Advertising & Branding

10 November, 2022 No Comments

The congress offers a range of pre, during and post-congress advertising and branding opportunities in both physical and digital formats. The promotional opportunities are categorised

Read More »

Networking & Lead Generation

10 November, 2022 No Comments

Ad-Hoc Meeting Rooms The congress offers a range of networking rooms and spaces to support your connection with delegates outside of o ur hosted partner

Read More »

Audience Engagement & Education

10 November, 2022 No Comments

<insert spex program and pricing overview> Partner Program See page partnership terms and conditions for promotion and usage conditions for pre-congress workshops, wetlabs and symposia

Read More »

Partnership Opportunities

10 November, 2022 No Comments

Partnership Tiers are calculated based on total spend in USD (excluding taxes) across sponsorship and exhibition. Excludes HCP (Health Care Professional) sponsorship and group registrations.

Read More »

FAQs

10 November, 2022 No Comments

What format will the 2024 congress be? The APGC Congress will be face-to-face. APGC 2024 Manila is a face-to-face congress. All sessions are hosted live

Read More »

Delegate Demographics

10 November, 2022 No Comments

0 + APGC 2024 Manila expected audience attendees APGC historial attendance 2022 Kuala Lumpur Audience primary interest: <insert 2022 rego data on primary interest. Reflect

Read More »

7th Asia-Pacific Glaucoma Congress

Co-hosted by the Philippine Academy of Ophthalmology, and the Philippine Glaucoma Society

Date
25-28 April 2024
Venue
SMX Manila Convention Centre
Contact

Thomas Howden
Partnership Manager
+61 2 9213 4016
Thomas.Howden@wearemci.com

Keep me updated

Do you want to receive the latest APGC updates? Sign up to our mailing list!

Useful Links

Follow us
#APGC2022
Facebook-square Twitter Linkedin-in Youtube Envelope
Designed and built by MCI Australia
Welcome to APGC 2022
Access Virtual Platform
Iridex

Iridex

At Iridex, we are redefining the glaucoma treatment paradigm with a versatile range of non-incisional, laser-based therapies: MicroPulse Laser Trabeculoplasty, MicroPulse Transscleral Laser Therapy, and Continuous-Wave Transscleral Cyclophotocoagulation. These therapies
provide physicians safe, effective, and versatile treatment options for a wide variety of glaucoma types and severities, to significantly reduce intraocular pressure and slow the progression of vision loss. More than 200,000 patients have been treated since 2015 with MicroPulse® TLT using the MicroPulse P3® Delivery Device. Visit iridex.com/webinars to learn how ophthalmologists and patients benefit from our non-incisional glaucoma procedures.

Kalson

Kalson Surgical

Bayer

Bayer Co. (Malaysia) Sdn Bhd

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. For more information, go to www.bayer.com.

DKSH_500x500

DKSH

DKSH is the leading growth partner for pharmaceutical companies in Asia. Our experts provide a range of integrated Market Expansion Services across the entire value chain, ranging from registration through to marketing, promotion and distribution.
Our capillary network reaches more than 130,000 hospitals, clinics, pharmacies, doctors and drugstores in Asia. Products are transported, stored and distributed efficiently thanks to our unmatched capacities and expertise in the region. Our solid infrastructure and dedication to compliance and quality reduce business risks for our partners.
We are committed to delivering the results you need to be successful. That’s why we continuously invest in our sales and marketing organization, which is fully embedded in our operations. Our teams work with clear measurements, activity-driven KPIs and standardized brand planning processes across the region. They are supported by regional Sales and Marketing Excellence and Business Development teams, allowing us to duplicate success across markets.
Headquartered and publicly listed in Switzerland, our local experts provide services to pharmaceutical companies in 13 Asian markets.

Glaukos Aventisin 500x500

Glaukos Corporation / Aventisin

Founded in 1998, Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.

We were the first company to bring to market Micro-Invasive Glaucoma Surgery (MIGS), the micro-invasive procedure that revolutionized the treatment and management of glaucoma. In 2012, we launched our first MIGS device—the iStent®—in the United States, followed by our next-generation iStent inject® device in September 2018 and iStent inject® W in September 2020.

In November 2019, Glaukos acquired Avedro, maker of the first and only FDA-approved cross-linking technology for progressive keratoconus. And we continue to seek to leverage our platform technologies to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies for
glaucoma, corneal health, and retinal diseases.

Our company completed an initial public offering in June of 2015, and our shares are traded on the New York Stock Exchange under the ticker symbol “GKOS”. Our global headquarters is located in Aliso Viejo, California, and we have additional locations in 9 regions around the world.